Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-08-14
2008-09-23
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07427629
ABSTRACT:
The present invention provides immunostimulatory compositions that include an immune response modifier portion paired with an antigenic portion.
REFERENCES:
patent: 4689338 (1987-08-01), Gerster
patent: 4698348 (1987-10-01), Gerster
patent: 4929624 (1990-05-01), Gerster et al.
patent: 4988815 (1991-01-01), Andre et al.
patent: 5037986 (1991-08-01), Gerster
patent: 5175296 (1992-12-01), Gerster
patent: 5238944 (1993-08-01), Wick et al.
patent: 5266575 (1993-11-01), Gerster
patent: 5268376 (1993-12-01), Gerster
patent: 5346905 (1994-09-01), Gerster
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5352784 (1994-10-01), Nikolaides et al.
patent: 5367076 (1994-11-01), Gerster
patent: 5376501 (1994-12-01), Mariën et al.
patent: 5389640 (1995-02-01), Gerster et al.
patent: 5395937 (1995-03-01), Nikolaides et al.
patent: 5446153 (1995-08-01), Lindstrom et al.
patent: 5482936 (1996-01-01), Lindstrom
patent: 5494916 (1996-02-01), Lindstrom et al.
patent: 5521289 (1996-05-01), Hainfeld et al.
patent: 5693811 (1997-12-01), Lindstrom
patent: 5741908 (1998-04-01), Gerster et al.
patent: 5756747 (1998-05-01), Gerster
patent: 5939090 (1999-08-01), Beaurline et al.
patent: 6028076 (2000-02-01), Hirota et al.
patent: 6039969 (2000-03-01), Tomai et al.
patent: 6069149 (2000-05-01), Nanba et al.
patent: 6083505 (2000-07-01), Miller et al.
patent: 6110929 (2000-08-01), Gerster et al.
patent: 6194338 (2001-02-01), Andolfatto et al.
patent: 6194425 (2001-02-01), Gerster et al.
patent: 6200592 (2001-03-01), Tomai et al.
patent: 6207646 (2001-03-01), Krieg et al.
patent: 6239116 (2001-05-01), Krieg et al.
patent: 6245776 (2001-06-01), Skwierczynski et al.
patent: 6329381 (2001-12-01), Kurimoto et al.
patent: 6331539 (2001-12-01), Crooks et al.
patent: 6339068 (2002-01-01), Krieg et al.
patent: 6340461 (2002-01-01), Terman
patent: 6376501 (2002-04-01), Isobe et al.
patent: 6376669 (2002-04-01), Rice et al.
patent: 6387938 (2002-05-01), Mizuguchi et al.
patent: 6406705 (2002-06-01), Davis et al.
patent: 6426334 (2002-07-01), Agrawal et al.
patent: 6451810 (2002-09-01), Coleman et al.
patent: 6476000 (2002-11-01), Agrawal
patent: 6518265 (2003-02-01), Kato et al.
patent: 6525064 (2003-02-01), Dellaria et al.
patent: 6545016 (2003-04-01), Dellaria et al.
patent: 6545017 (2003-04-01), Dellaria et al.
patent: 6558951 (2003-05-01), Tomai et al.
patent: 6573273 (2003-06-01), Crooks et al.
patent: 6660747 (2003-12-01), Crooks et al.
patent: 7030129 (2006-04-01), Miller et al.
patent: 2002/0022248 (2002-02-01), Xu et al.
patent: 2002/0055517 (2002-05-01), Smith
patent: 2002/0058674 (2002-05-01), Hedenstrom et al.
patent: 2003/0022302 (2003-01-01), Lewis et al.
patent: 2003/0139364 (2003-07-01), Krieg et al.
patent: 2004/0014779 (2004-01-01), Gorden et al.
patent: 2004/0023870 (2004-02-01), Dedera et al.
patent: 2005/0220883 (2005-10-01), O'Hagan et al.
patent: 0 394 026 (1990-10-01), None
patent: 1 104 764 (2001-06-01), None
patent: 9-208584 (1997-08-01), None
patent: 11-80156 (1999-03-01), None
patent: 11-222432 (1999-08-01), None
patent: 2000-247884 (2000-09-01), None
patent: WO 00/40228 (2000-07-01), None
patent: WO 00/47719 (2000-08-01), None
patent: WO 00/75304 (2000-12-01), None
patent: WO 00/76505 (2000-12-01), None
patent: WO 00/76518 (2000-12-01), None
patent: WO 01/74343 (2001-10-01), None
patent: WO 02/36592 (2002-05-01), None
patent: WO 02/46188 (2002-06-01), None
patent: WO 02/46189 (2002-06-01), None
patent: WO 02/46190 (2002-06-01), None
patent: WO 02/46191 (2002-06-01), None
patent: WO 02/46192 (2002-06-01), None
patent: WO 02/46193 (2002-06-01), None
patent: WO 02/46194 (2002-06-01), None
patent: WO 02/46749 (2002-06-01), None
patent: WO 02/085905 (2002-10-01), None
patent: WO 02/102377 (2002-12-01), None
patent: WO 03/020889 (2003-03-01), None
patent: WO 03/043572 (2003-05-01), None
patent: WO 03/045391 (2003-06-01), None
patent: WO 03/086280 (2003-10-01), None
patent: WO 03/089602 (2003-10-01), None
Agrawal, et al. Nature Biotech 22: 1534-1537, 2004 Antisense and siRNA as agonists of Toll-like receptors.
Bernstein, et al. Vaccine 13: 72-76, 1995 ‘Effect of imiquimod as an adjuvant for immunotherapy of genital HSV in guinea-pigs’.
Kirkley, et al. Scand. J. Immunol. 43: 431-438, 1996 ‘Adjuvant Properties of Montanide CSA 720 with a recombinant HIV P17 gag Protein and synthetic peptide antigens’.
Du, et al. World J. Gastroenterol. 9(1): 108-111, 2003 ‘HBV DNA vaccine with adjuvant cytokines induced specific immune response against HBV infection’.
Aduzzi, a, Prions and the immune system: a journey through gut, spleen, and the nerves, Adv. Immunol., 81:123, 2003 (Abstract only).
Adamsson et al., Novel Immunostimulatory agent based on CpG oligonucleotide linked to the nontoxic B subunit of cholera toxin, J. immunol., 176(8):4902-13, Apr. 15, 2006.
Muller et al., Specific antibody response towards predicted epitopes of the epidermal growth factor receptor induced by a thermostable synthetic peptide adjuvant conjugate, Clin. Exp. Immunol., 78(3):499-504, Dec. 1989.
Francklyn, C., Aminoacyl-tRNA Synthetases: Versatile Players in the Changing Theater of Translation, RNA, vol. 8, pp. 1363-1372 (2002).
Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., McGraw-Hill, NY, (1996).
Nagase, H., et al., The Pharmacological Profile of δ Opioid Receptor Ligands, (+) and (−) TAN-67 on Pain Modulation, Life Sciences, vol. 68, pp. 2227-2231 (2001).
Kick, E.K., et al., Structure-Based Design and Combinatorial Chemistry Yield Low Nanomolar Inhibitors of Cathepson D, Chemistry & Biology, vol. 4, No. 4, pp. 297-307 (1997).
Immunobiology, The Immune System in Health and Disease, Third Edition, Janeway, And Travers, Ed., 1997.
Gorden et al., “Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8”,The Journal of Immunology, 2005, vol. 174, pp. 1259-1268.
Sauder et al., “Randomized, Single-Blind, Placebo-Controlled Study of Topical Application of the Immune Response Modulator Resiquimod in Healthy Adults”,Antimicrobial Agents and Chemotherapy, Dec. 2003, vol. 47, No. 12, pp. 3846-3852.
Akira S. et al., “Recognition of pathogen-associated molecular patterns by TLR family”,Immunology Letters, 2003, vol. 85, pp. 85-95.
Ozinsky A. et al., “The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors”,Proc. Nat. Acad. Sci., Dec. 2000, vol. 97, No. 25, pp. 13766-13771.
Heil et al.; “Synthetic immunostimulatory compounds activate immune cells via TLR7 and TLR8”; 33th Annual Meeting of the Deutsche Gessellschaft für Immunologie, Marburg 2002—Abstract C.6.
Vasllakos et al.,Cellular Immunology, vol. 204, pp. 64-74 (2000).
Wagner et al.,Cellular Immunology, vol. 191, pp. 10-19 (1999).
Izumi et al.; “1H-Imidazo[4,5-c]quinoline Derivatives as Novel Potent TNK-α Suppressors: Synthesis and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1H-imidazo[4,5-c]quinolines or 1H-imidazo[4,5-c]pyridines”; Bioorganic & Medicinal Chemistry; 11; (2003) pp. 2541-2550.
Testerman, et al., “Cytokine Induction by the Immunomodulators Imiquimod and S-27609”,Journal of Leukocyte Biology, vol. 58, pp. 365-372, Sep. 1995.
Chollet, et al, “Development of a Topically Active Imiquimod Formulation”,Pharmaceutical Development and Technology, 4(1), pp. 35-43 (1999).
Hornung et al., “Quantitative Expression of Toll-Like Receptor 1-10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides1”,The Journal of Immunology, 2002, 168; pp. 4531-4537.
Hemmi et al., “Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent Signaling pathway”,Nature Immunology, vol. 3, No. 2; Feb. 2002 pp. 196-200.
Medzhitov, “Toll-Like Receptors and Innate Immunity”,Nature Reviews Immunology, Vo. 1, Nov. 2001, pp. 135-145.
Jurk et al. &#x
Griesgraber George W.
Kedl Ross M.
Wightman Paul D.
Zarraga Isidro Angelo E.
3M Innovative Properties Company
Mertz Prema
Ringsred Ted K.
LandOfFree
Immunostimulatory compositions and methods of stimulating an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunostimulatory compositions and methods of stimulating an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunostimulatory compositions and methods of stimulating an... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3986492